Rivastigmine Clinical Trials

Size	Price	Qty
20mg	USD 147
100mg	USD 370

Clinical Trials

Numerous clinical trials spanning Phase 1 through Phase 4 evaluate the therapeutic utility of rivastigmine across neurological and psychiatric indications, such as Alzheimer's disease, Parkinson's disease dementia, delirium, depressive disorder, and methamphetamine dependence. Encompassing completed, recruiting, and terminated recruitment statuses, these studies focus on key outcomes including safety, efficacy, and tolerability. They are sponsored by pharmaceutical corporations such as Novartis, academic medical centers, and government institutes like NIDA.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04366518	RECRUITING	Hallucinations, Auditory; Psychosis	Yale University	2021-07-15	EARLY_PHASE1
NCT06382649	RECRUITING	Anticholinergic Toxicity	Washington University School of Medicine	2026-06	PHASE2
NCT06399679	SUSPENDED	Anticholinergic Toxicity	Washington University School of Medicine	2024-11-04	PHASE2
NCT03454646	NOT_YET_RECRUITING	Alzheimer Disease; Cholinesterase Inhibitors	University Hospital, Bordeaux	2024-06-01	PHASE4
NCT07545382	COMPLETED	Anticholinergic Delirium; Clozapine Poisoning; Antipsychotic Toxicity; CNS Depression; Hypoactive Delirium; Tricyclic Antidepressant Poisoning; Procyclidine Induced Delirium	Alexandria University	2025-12-08	PHASE4
NCT07208344	RECRUITING	Alzheimer Disease (AD)	Anhui Provincial Hospital	2025-07-31	EARLY_PHASE1
NCT05768126	UNKNOWN	Depressive Disorder	UMC Utrecht	2021-09-29	PHASE4
NCT06537076	RECRUITING	Lewy Body Dementia	Yonsei University	2024-01-01	PHASE2
NCT06702124	RECRUITING	Alzheimer Disease	I.R.C.C.S. Fondazione Santa Lucia	2023-12-01	PHASE3
NCT04226248	COMPLETED	Parkinson Disease	University of Bristol	2020-01-02	PHASE3
NCT05853341	COMPLETED	Healthy	Luye Pharma Group Ltd.	2023-05-02	PHASE1
NCT05883124	COMPLETED	Bioequivalence	SocraTec R&D GmbH	2023-04-17	PHASE1
NCT07464340	COMPLETED	Bioequivalence Study in Healthy Subjects	Zodiac Produtos Farmaceuticos S.A.	2023-05-12	PHASE1
NCT02989402	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2018-12-31	PHASE4
NCT02839642	COMPLETED	Progressive Supranuclear Palsy (PSP)	Assistance Publique Hopitaux De Marseille	2016-07-26	PHASE3
NCT05768126	Recruiting	Depressive Disorder	UMC Utrecht\|ZonMw: The Netherlands Organisation for Health Research and Development\|St. Antonius Hospital\|Tergooi Hospital	2021-09-29	Phase 4
NCT03915626	COMPLETED	Bioavailability	University of Maryland, Baltimore	2019-10-04	EARLY_PHASE1
NCT03957174	COMPLETED	Healthy	University of Oxford	2019-06-01
NCT04189666	COMPLETED	Delirium	Ain Shams University	2019-11-18	PHASE1; PHASE2
NCT03840837	COMPLETED	Parkinson Disease; Parkinson Disease Dementia	University of Maryland, Baltimore	2019-05-02	PHASE4
NCT02444637	COMPLETED	Alzheimer Disease; CVA (Cerebrovascular Accident)	National Neuroscience Institute	2015-04	PHASE4
NCT03659435	COMPLETED	Bioequivalence	SocraTec R&D GmbH	2018-08-22	PHASE1
NCT01856738	TERMINATED	Parkinson's Disease	Amsterdam UMC, location VUmc	2013-11	PHASE4
NCT03573050	COMPLETED	Bioequivalence	SocraTec R&D GmbH	2018-05-16	PHASE1
NCT02703636	COMPLETED	Mild to Moderate Alzheimer's Disease	Novartis Pharmaceuticals	2016-05-09	PHASE4
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT02063269	UNKNOWN	Alzheimer's Disease	Seoul National University Hospital	2014-02
NCT00223691	COMPLETED	Autonomic Failure; Orthostatic Hypotension	Vanderbilt University	2002-03	PHASE1
NCT01380288	COMPLETED	Alzheimer's Disease	Dong-A University	2011-06
NCT01670526	COMPLETED	Traumatic Brain Injury; Cognitive Impairment	VA Office of Research and Development	2012-12	PHASE3
NCT01362686	TERMINATED	Dementia; Alzheimer's Disease	Indiana University	2011-04
NCT01948791	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2014-08	PHASE4
NCT01487317	COMPLETED	Delirium	Assistance Publique - Hôpitaux de Paris	2011-06	PHASE3
NCT01677754	COMPLETED	Alzheimer's Disease	Hoffmann-La Roche	2012-10-24	PHASE2
NCT01585272	COMPLETED	Alzheimer's Dementia	Novartis Pharmaceuticals	2012-08	PHASE4
NCT01519271	COMPLETED	Parkinson's Disease; Mild Cognitive Impairment	University of Pennsylvania	2011-12	PHASE4
NCT01030692	COMPLETED	Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse	Baylor College of Medicine	2009-01	PHASE1
NCT01614886	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2012-07	PHASE3
NCT02413554	COMPLETED	Delirium	Chung-Ang University Hospital	2013-04	PHASE4
NCT01348282	COMPLETED	Neurocognitive Disturbance; HIV Infection	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	2011-05	PHASE4
NCT01084135	COMPLETED	Down Syndrome	Duke University	2009-11	PHASE1; PHASE2
NCT01529619	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2012-03	PHASE4
NCT01399125	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2011-07	PHASE3
NCT01602198	TERMINATED	Mild Cognitive Disorder; Mild Cognitive Impairment	The Cleveland Clinic	2011-06
NCT01585272	Completed	Alzheimer''s Dementia	Novartis Pharmaceuticals\|Novartis	2012-08	Phase 4
NCT00948766	COMPLETED	Alzheimer's Disease	Novartis	2009-07	PHASE4
NCT01696123	COMPLETED	Alzheimer Disease	Shahid Beheshti University of Medical Sciences	2011-01	PHASE2
NCT01183806	COMPLETED	Alzheimer Disease	Federal University of Bahia	2010-07	PHASE3
NCT01047579	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2010-04	PHASE4
NCT00767091	COMPLETED	Parkinson's Disease; Apathy; no Dementia	University Hospital, Lille	2009-03	PHASE3
NCT00731224	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2008-07	PHASE4
NCT00506415	COMPLETED	Alzheimer Disease	Novartis Pharmaceuticals	2007-06	PHASE3
NCT00988117	COMPLETED	Parkinsons Disease With Dementia; Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems	University of California, San Francisco	2010-04	PHASE4
NCT00881205	TERMINATED	Multiple Sclerosis; Cognitive Impairment	Novartis Pharmaceuticals	2009-04	PHASE4
NCT00623103	COMPLETED	Parkinson's Disease Dementia	Novartis	2008-01	PHASE3
NCT01073319	COMPLETED	Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse	Baylor College of Medicine	2009-07	PHASE1
NCT00835159	COMPLETED	Delirium; Postoperative Cognitive Dysfunction	NYU Langone Health	2008-12	PHASE4
NCT00704301	TERMINATED	Delirium	UMC Utrecht	2008-11	PHASE4
NCT00522015	UNKNOWN	Progressive Supranuclear Palsy; Dementia	University Hospital Tuebingen	2008-02	PHASE2
NCT00748007	COMPLETED	Down Syndrome	National Taiwan University Hospital	2008-01
NCT01025466	COMPLETED	Alzheimer's Disease	Inha University Hospital	2008-12	PHASE4
NCT01073319	Completed	Methamphetamine Dependence\|Substance Abuse\|Methamphetamine Abuse	Baylor College of Medicine\|National Institute on Drug Abuse (NIDA)	2009-07	Phase 1
NCT01312363	Completed	Alzheimer''s Disease	Seoul National University Hospital\|Seoul National University Bundang Hospital\|Seoul St. Mary''s Hospital\|Korea University\|Bobath Memorial Hospital\|Chung-Ang University Hosptial Chung-Ang University College of Medicine\|Hanyang University\|Kwandong University Myongji Hospital\|Inha University Hospital\|SungAe General Hospital\|Ewha Womans University\|Inje University\|Hanyang University Seoul Hospital\|Kyunghee University Medical Center\|Hallym University Medical Center\|Pusan National University Hospital\|Konyang University Hospital\|Wonkwang University Sanbon Medical Center\|Yong-in Hyoja Geriatric Hospital\|Jeju National University\|Dong-A University Hospital	2009-06	--
NCT00549601	COMPLETED	Alzheimer's Disease	Novartis	2007-09	PHASE4
NCT00624663	COMPLETED	Rivastigmine Toxicity	Tel-Aviv Sourasky Medical Center	2009-01
NCT00423085	COMPLETED	Alzheimer's Disease	Novartis Pharmaceuticals	2007-01	PHASE3
NCT00766363	COMPLETED	Alzheimer's Disease; Central Nervous System Diseases	FORUM Pharmaceuticals Inc	2008-10	PHASE1
NCT00624663	Completed	Rivastigmine Toxicity	Tel-Aviv Sourasky Medical Center\|Medical Corps Israel Defense Force	2009-01	Not Applicable
NCT00622713	COMPLETED	Alzheimer's Disease	Novartis	2008-01	PHASE4
NCT00627848	COMPLETED	Alzheimer' Disease	Kuopio University Hospital	2007-03
NCT00561392	COMPLETED	Alzheimer's Disease	Novartis	2007-11	PHASE4
NCT00599287	TERMINATED	Delirium	UMC Utrecht	2008-02	PHASE3
NCT00428389	COMPLETED	Alzheimer's Disease	Novartis	2007-01	PHASE3
NCT00669344	COMPLETED	Cognitive Impairment	Singapore General Hospital	2006-02	PHASE4
NCT00158210	COMPLETED	Substance-Related Disorders	National Institute on Drug Abuse (NIDA)	2006-05	PHASE1
NCT00219232	COMPLETED	Alzheimer's Disease	Novartis	2003-02	PHASE3
NCT00130338	COMPLETED	Vascular Dementia	Novartis	2002-02	PHASE3
NCT00099216	COMPLETED	Vascular Dementia	Novartis Pharmaceuticals	2001-08	PHASE3
NCT00234637	COMPLETED	Alzheimer's Disease	Novartis	2003-11	PHASE4
NCT00171795	COMPLETED	Traumatic Brain Injury	Novartis	2002-11	PHASE3
NCT00219245	COMPLETED	Traumatic Brain Injury With Persistent Cognitive Deficits	Novartis	2002-11	PHASE4
NCT01146041	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2004-02	PHASE1
NCT01146067	COMPLETED	Healthy	Dr. Reddy's Laboratories Limited	2004-01	PHASE1
NCT00257868	COMPLETED	Delirium	University Hospital, Basel, Switzerland	2006-01	PHASE3
NCT00000174	COMPLETED	Alzheimer Disease; Cognition Disorders	Novartis		PHASE3
NCT00102284	TERMINATED	Healthy	University Hospital Muenster	2004-03	PHASE4
NCT00134953	TERMINATED	Cognitive Symptoms	Novartis	2003-01	PHASE3
NCT00102856	SUSPENDED	Healthy	University Hospital Muenster	2005-01	PHASE4
NCT00305903	COMPLETED	Alzheimer's Disease	Novartis	2006-03	PHASE4
NCT00099242	COMPLETED	Alzheimer's Disease; Dementia, Alzheimer Type	Novartis Pharmaceuticals	2003-11	PHASE3
NCT00104442	COMPLETED	Alzheimer's Disease	Novartis	2003-10	PHASE4

(data from https://clinicaltrials.gov, updated on 2025-06-05)

Check the Rivastigmine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Rivastigmine acts as a cholinesterase inhibitor that reversibly binds to acetylcholinesterase and butyrylcholinesterase, blocking the enzymatic hydrolysis of acetylcholine within synaptic clefts. This inhibition elevates central synaptic acetylcholine concentrations and restores neurotransmission, thereby mitigating cognitive decline in clinical trial indications such as Alzheimer's disease and Parkinson's disease dementia.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).